Doctor Q&A: “What Are Patient Outcomes For Mitral Valve Re-Repairs?” asks Sharon

Written By: Allison DeMajistre, BSN, RN, CCRN

Medical Expert: Sabet Hashim, MD, Chairman of Cardiac Surgery, Hartford Healthcare

Reviewed By: Adam Pick, Patient Advocate, Author, and Website Founder

Published: June 3, 2024

According to The Journal of Thoracic and Cardiovascular Surgery, mitral valve repair is the preferred treatment to correct mitral regurgitation. Compared to mitral valve replacement, a repair has lower risk of operative mortality, preserves left ventricular function, and reduces the risk of blood clots, endocarditis, and bleeding related to lifetime anticoagulation therapy.

Unfortunately, patients who undergo mitral valve repair surgery may require re-repair. Failure of the initial repair can result from problems with the original procedure or continued degenerative disease of the valve. Regardless of the reasons for repair failure, when patients need to return to the operating room for re-repair, they want assurance that it will succeed.

To this point, we received a patient question from Sharon, who asked, “Is anyone keeping data specifically about the durability of valve re-repairs after a repair has failed? If so, what are the outcomes?” To answer Sharon’s question,  I met with Dr. Sabet Hashim, the Chairman of Cardiac Surgery at Hartford Healthcare in Hartford, Connecticut, who specializes in mitral valve repair.

 

 

Key Learnings About Mitral Valve Re-Repair Outcomes

  • Dr. Hashim was not aware of specific research about the long-term outcomes of mitral valve re-repair operations. However, he did note that approximately 5% of first time mitral valve repairs may fail. Dr. Hashim said, “I don’t have data on the longevity of re-repair, but if I were to think conceptually about this issue, millions of patients have myxomatous valve disease and they have what we call prolapse. Only five percent of them develop mitral regurgitation leading to surgery.”
  • Dr. Hashim suggested that it is appropriate to predict a similar outcome for mitral valve re-repairs compared to first-time mitral valve repair procedures. “When we operate on the patient, we are removing the active defect in the valve that caused the regurgitation but we are keeping the patient with myxomatous valve disease,” Dr. Hashim said. “So we can predict five percent of them will recur. So when we operate on those patients, we can apply the same rule.”
  • According to Dr. Hashim, patients should actively pursue a mitral valve re-repair procedure compared to a mitral valve replacement operation. Dr. Hashim told us. “The prognosis of a re-repair is far better than the prognosis of any replacement for the patient.”

 

Thank you, Dr. Hashim and Hartford Healthcare!

On behalf of patients at HeartValveSurgery.com and patients across the world, thank you, Dr. Hashim, for sharing your thoughts on how re-repairs can help patients with a durable, lasting mitral valve. And thank you for everything you and your team are doing at Hartford Healthcare.

Keep on tickin!
Adam

P.S. For the deaf and hard-of-hearing members of our patient community, I have provided a transcript of this interview with Dr. Hashim below.

Written by Adam Pick
- Patient & Website Founder

Adam Pick, Heart Valve Patient Advocate

Adam Pick is a heart valve patient and author of The Patient's Guide To Heart Valve Surgery. In 2006, Adam founded HeartValveSurgery.com to educate and empower patients. This award-winning website has helped over 10 million people fight heart valve disease. Adam has been featured by the American Heart Association and Medical News Today.

Adam Pick is a heart valve patient and author of The Patient's Guide To Heart Valve Surgery. In 2006, Adam founded HeartValveSurgery.com to educate and empower patients. This award-winning website has helped over 10 million people fight heart valve disease. Adam has been featured by the American Heart Association and Medical News Today.

Video Transcript:

Adam Pick: Hi everybody, it’s Adam with heartvalvesurgery.com. We’re in San Antonio, Texas at the annual meeting of The Society of Thoracic Surgeons. I am thrilled to be joined by Dr. Sabet Hashim, who is the chairman of Cardiac Surgery at Hartford Healthcare in Hartford, Connecticut.

Adam Pick: Dr. Hashim, it is great to see you again and thanks so much for being with me today. Oh, thank you.

Dr. Sabet Hashim: It’s my pleasure.

Adam Pick: We’re here at the conference and we’re learning a lot. At the same time we’re getting questions from patients. This one came in and it’s in your specialty. I know you’ve done a lot of mitral valve repair work. This comes in from Sharon and she asks, is anyone keeping data specifically about the durability of valve rere repairs after a repair has failed? If so,

Dr. Sabet Hashim: what are the outcomes?

Dr. Sabet Hashim: I don’t have, uh, data on, uh, the longevity of, uh, re repair, but if I were to think, uh, conceptually about this issue, uh, millions of patients have myxomatous valve disease and they have what we call prolapse. Only 5 percent of them, uh, develop severe mitral regurgitation leading to surgery.

Dr. Sabet Hashim: So when we operate on that patient, we are Uh, removing the active, uh, defect in the valve that caused the regurgitation, but we are keeping the patient with myxomatous valve disease. So I would say we can predict that 5 percent of them will recur. So when we reoperate on those patients, we can apply the same rule.

Dr. Sabet Hashim: Another 5 percent will recur over the lifetime of the patient. Now, knowing that, uh, the prognosis of a re repair is far better. than the prognosis of any replacement for that patient.

Adam Pick: Well, well, Dr. Hashim, although you didn’t have the specific research, I love your thinking in how re repairs can help the patient with a durable, lasting mitral valve.

Adam Pick: And on behalf of the patients at heartvalvesurgery. com, patients all over the world, Dr. Hashim, thanks for everything you and your team are doing at Hartford HealthCare.

Dr. Sabet Hashim: Thank you for the opportunity.